<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Aliotta, Philip J.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Improvement in UI with OnabotulinumtoxinA Maintained over 4 Years in Patients with MS</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-06-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">17-18</style></pages><abstract><style  face="normal" font="default" size="100%">A long-term extension trial demonstrated improvement in urinary incontinence (UI) as a result of neurogenic detrusor overactivity (NDO) caused by multiple sclerosis (MS). This article presents data from A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis trial [NCT00876447; Aliotta PJ et al. ACTRIMS/ECTRIMS 2014; (poster P905)].</style></abstract><number><style face="normal" font="default" size="100%">29</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>